Skip to main content
Equibles

Harith Rajagopalan

CEO

Fractyl Health, Inc. (GUTS)

Board Member

Fractyl Health, Inc. (GUTS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Fractyl Health, Inc. publishes a filing, an earnings call transcript or a press release.

Get GUTS alerts

About Harith Rajagopalan

Harith Rajagopalan is recorded as CEO and Board Member at Fractyl Health, Inc. (GUTS). The newest filing on record that lists Harith Rajagopalan as CEO and Board Member at Fractyl Health, Inc. (GUTS) is dated April 24, 2026. The proxy statement of Fractyl Health, Inc. reports total compensation of $6,414,290 for Harith Rajagopalan in fiscal 2025, including a base salary of $610,000. Disclosed compensation is on record for 3 fiscal years. Harith Rajagopalan has spoken on 10 earnings calls and 2 other investor events across 1 company, most recently for Fractyl Health, Inc. on September 14, 2026. Fractyl Health, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Fractyl Health, Inc. includes Lara Smith Weber (CFO), Sarah Toomey (General Counsel), Christopher Thompson, M.D. (Board Member) and 1 other.

Harith Rajagopalan on recent calls

“We are developing Revita, duodenal mucosal resurfacing, for post-GLP1 weight maintenance. We have pivotal data coming in early Q4, just several weeks away, for potentially the first therapeutic option that has the potential to deliver a durable metabolic reset for people with obesity and type 2 diabetes.”
CEO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“Yeah, so Fractal's focus is on developing therapies that offer the potential for durable metabolic benefit against obesity, type 2 diabetes, and related metabolic disease.”
CEO, Canaccord Genuity 46th Annual Growth Conference ·
“Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing each month. What happens after discontinuation is now well characterized.”
CEO, Fractyl Health 2Q 2026 Financial Results and Business Update Conference Call ·
“Tens of millions of Americans are now on GLP-1 therapy, and over 1 million people are discontinuing GLP-1s each month in the United States. What happens next is increasingly well-characterized.”
CEO, Fractyl Health, Inc. Q1 FY2026 Earnings Call ·
“Millions of Americans are starting GLP-1 therapy. Most of them will stop within a year. Data show that when they stop, the weight comes back, approximately 10% of their body weight within six months, and approximately 15% within 12 months.”
CEO, Fractyl Health, Inc. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Fractyl Health, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Fractyl Health, Inc. (GUTS) $610,000 $6,414,290
2024 Fractyl Health, Inc. (GUTS) $604,462 $4,856,361
2023 Fractyl Health, Inc. (GUTS) $550,000 $3,561,774

Recent activity